List of Devices Companies in Italy - 8

BetaGlue Therapeutics is a clinical stage oncology company that has developed an advanced radiotherapy platform enabling localised targeted treatment of both unresectable solid tumours and also treatment of surgical resection margins called YntraDose.

Galileo Research origins lie in 1972 as the Research Centre of Istituto Gentili, an Italian pharmaceutical company founded in 1917. At the beginning of the ‘80s, scientists at the Gentili Research Centre discovered and developed new molecules in the class of bisphosphonates and in the field of bone diseases, in particular clodronate and alendronate. The Research Centre continued to work in the field of bone and joint metabolism and also expanded its knowledge and activities to the areas of oncology and CNS. Galileo Research was established in July 2011.

Intrauma is a medical devices company that specializes in providing healthcare solutions for trauma care through innovative surgical instruments.

Lo.Li. Pharma INTERNATIONAL is a branch of Lo.Li. Pharma Srl, a growing pharmaceutical company, based in Rome, dedicated to the research, development and out-licencing distribution of Medical Devices and Functional Dietary Supplements. The company's key success factor is the continuous effort in developing new products while responding to the needs of patients and of new treatments and prevention tools for the medical class. The innovative formulations of Lo.Li. Pharma have attracted the attention of many foreign Companies and private citizens alike, all looking forward to have Loli's products available in their own countries. With more than 20 products in our portfolio and our brand presented in more than 50 countries, we are always seeking out-licensing opportunities with key strategic partners for long term exclusive distribution. For further information, kindly contact us at info@lolipharmainternational.com or call +39 06.88379670

At Microbion, we are developing a new class of therapeutic drugs to tackle the unmet needs of rare, chronic, and serious diseases. Our lead drug candidate, pravibismane, is a first-in-class therapeutic with a novel triad of activities: anti-infective, antibiofilm, and anti-inflammatory. These synergistic properties uniquely position pravibismane to address conditions where conventional treatments often fail. We are advancing multiple pravibismane formulations through clinical development, focusing on indications with significant unmet needs: - Topical pravibismane for diabetic foot ulcers/infections: Phase 3 studies planned for 2025 - Local/surgical pravibismane for orthopedic infections: Phase 2a studies completed - Inhaled pravibismane for pulmonary diseases including Nontuberculous mycobacteria lung infections: Ready for first-in-human Phase 1 studies Pravibismane has been granted FDA Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug designations, underscoring its disruptive potential. To date, pravibismane development has been supported by over $22M in grants awarded from leading organizations, including the U.S. Department of Defense, NIH, CARB-X, and the Cystic Fibrosis Foundation. We are actively seeking strategic licensing and development partners to advance Phase 3 trials, explore new indications (e.g., immunomodulation and inflammation), and bring pravibismane to patients worldwide.

Building Brain Computers Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normal daily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca'​ Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. ​ Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics and biotechnologies.

WHO WE ARE PQE Group is a women-owned Contract Quality Organisation and Complete Quality Solution provider for GCP, GLP, GMP, GVP & GDP areas in the Life Science Industry. As an international group of over 2000 employees (40% of whom are female), we are composed of 43 nationalities and have experience working in more than 25 languages. PQE Group has an excellent history of supporting companies of all sizes and exceeding compliance standards from our 40 global offices. We are dedicated to creating value for our customers by putting our multidisciplinary teams and knowledge at their service, allowing our clients to achieve and maintain compliance with the latest regulations, and contributing to creating a safer pharmaceutical environment. WHAT WE DO Since 1998, PQE Group has successfully completed more than 15,000 projects worldwide while serving our 1400+ medical device and pharmaceutical clients. We deliver turnkey quality solutions while focusing on offering exceptional cost-effectiveness and maintaining the highest quality of care for our customers. With our extensive experience, effective project management, and exceptional cost-effectiveness, PQE's solutions are proven to be the winning combination for global corporations of all sizes. WHERE WE'RE GOING We at PQE Group strongly believe that our success is tied to the well-being of the communities and environment around us. We understand that change must come from ourselves first – so we take action through social responsibility goals like sustainable development, gender equality, protection of the environment, and health and safety. PQE Group actively works to achieve our ambitious objectives to foster social change and environmental stability by collaborating with important programs and charity associations around the world.

We make the injection of medicines safer - keeping people safe from infections! Roncadelle Operations is committed to increasing the safety of drug injections and improving the protection of patients and healthcare workers. We are dedicated to reducing the spread of infectious diseases and promoting safer healthcare. Our product portfolio includes a range of patented safety syringes and needle protection systems for pre-filled syringes and cartridges. They are easy to use, offer good value for money and meet current and increasingly stringent regulatory and legal requirements. As a drug delivery device and packaging specialist, we offer value-added services from design to commercialization with scale-up manufacturing solutions. Our services range from customized user-centered design and prototyping to high-quality end-to-end manufacturing solutions. This reflects our commitment to excellence in the healthcare and pharma industry. From the heart of Europe, Roncadelle Operations offers design expertise and state-of-the-art cleanroom production capabilities in proximity to our clients in the pharmaceutical and healthcare industries. We are happy to service your needs! Let's talk.